J&J shares down despite guidance raise as MedTech revenues disappoint

What happened: Johnson & Johnson reported a Q3 beat on both revenue and earnings and raised its 2026 sales and adjusted earnings guidance, but MedTech revenues disappointed and shares fell. Key numbers: Shares down about 6% at noon ET. Why it matters: The MedTech revenue shortfall outweighed the Q3 beat and the guidance raise, weighing on the stock despite the improved 2026 outlook.

J&J shares fell on disappointing MedTech revenues despite raised guidance.

J&J shares fell on disappointing MedTech revenues despite raised guidance. — impact context not separately stored; see What changed.